| Acute Home Healthcare Inc | |
| 4303 Vineland Rd Ste F-12, Orlando, Florida 32811 | |
| (321) 594-5656 | |
| Name | Acute Home Healthcare Inc |
|---|---|
| Location | 4303 Vineland Rd Ste F-12, Orlando, Florida |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 109032 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 32701, 32703, 32707, 32708, 32709, 32712, 32714, 32730, 32732, 32746, 32750, 32751, 32765, 32766, 32771, 32773, 32777, 32779, 32789, 32792, 32798, 32801, 32803, 32804, 32805, 32806, 32807, 32808, 32809, 32810, 32811, 32812, 32817, 32818, 32819, 32820, 32821, 32822, 32824, 32825, 32826, 32827, 32828, 32829, 32832, 32833, 32835, 32836, 32837, 32839, 33896, 34734, 34741, 34743, 34744, 34746, 34747, 34758, 34759, 34760, 34761, 34769, 34771, 34772, 34786, 34787 |
| NPI Number | 1649782624 |
| Organization Name | ACUTE GOLD HOME CARE LLC |
| Address | 4303 Vineland Rd Ste F12, Orlando, FL 32811 |
| Phone Number | 321-594-5656 |
News Archive
The drop in criminal prosecutions indicates a shift for federal law enforcement agencies, which have increasingly targeted schemes aimed at mortgage lending, financial institutions and Medicare, the government [health] insurance plan for the elderly.
University of Sydney research provides new evidence that nanoparticles, which are present in many food items, may have a substantial and harmful influence on human health.
Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma announced today that the companies have entered into a development and commercialization agreement for LPLchip(TM), a diagnostic tool to rapidly diagnose patients with complete and partial lipoprotein lipase deficiency (LPLD). AMT has developed Glybera(R) as a gene therapy for patients with this disease.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.
› Verified 3 days ago
| NPI Number | 1770707150 |
| Organization Name | ACUTE HOME HEALTHCARE, INC. |
| Address | 4303 Vineland Road, Suite F-12, Orlando, FL 32811 |
| Phone Number | 321-594-5656 |
News Archive
The drop in criminal prosecutions indicates a shift for federal law enforcement agencies, which have increasingly targeted schemes aimed at mortgage lending, financial institutions and Medicare, the government [health] insurance plan for the elderly.
University of Sydney research provides new evidence that nanoparticles, which are present in many food items, may have a substantial and harmful influence on human health.
Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma announced today that the companies have entered into a development and commercialization agreement for LPLchip(TM), a diagnostic tool to rapidly diagnose patients with complete and partial lipoprotein lipase deficiency (LPLD). AMT has developed Glybera(R) as a gene therapy for patients with this disease.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.
› Verified 3 days ago
| NPI Number | 1821482415 |
| Organization Name | ACUTE HOME HEALTH AIDES |
| Address | 4303 Vineland Rd, Suite F-12, Orlando, FL 32811 |
| Phone Number | 321-594-5656 |
News Archive
The drop in criminal prosecutions indicates a shift for federal law enforcement agencies, which have increasingly targeted schemes aimed at mortgage lending, financial institutions and Medicare, the government [health] insurance plan for the elderly.
University of Sydney research provides new evidence that nanoparticles, which are present in many food items, may have a substantial and harmful influence on human health.
Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma announced today that the companies have entered into a development and commercialization agreement for LPLchip(TM), a diagnostic tool to rapidly diagnose patients with complete and partial lipoprotein lipase deficiency (LPLD). AMT has developed Glybera(R) as a gene therapy for patients with this disease.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.
› Verified 3 days ago
| Quality Rating: |
News Archive
The drop in criminal prosecutions indicates a shift for federal law enforcement agencies, which have increasingly targeted schemes aimed at mortgage lending, financial institutions and Medicare, the government [health] insurance plan for the elderly.
University of Sydney research provides new evidence that nanoparticles, which are present in many food items, may have a substantial and harmful influence on human health.
Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma announced today that the companies have entered into a development and commercialization agreement for LPLchip(TM), a diagnostic tool to rapidly diagnose patients with complete and partial lipoprotein lipase deficiency (LPLD). AMT has developed Glybera(R) as a gene therapy for patients with this disease.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.
› Verified 3 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 96.7 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 98.1 | 98.6 |
| How often the home health team checked patients’ risk of falling | 99.6 | 99.6 |
| How often the home health team checked patients for depression | 90.1 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 80.9 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 52.8 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 98 | 96.4 |
News Archive
The drop in criminal prosecutions indicates a shift for federal law enforcement agencies, which have increasingly targeted schemes aimed at mortgage lending, financial institutions and Medicare, the government [health] insurance plan for the elderly.
University of Sydney research provides new evidence that nanoparticles, which are present in many food items, may have a substantial and harmful influence on human health.
Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma announced today that the companies have entered into a development and commercialization agreement for LPLchip(TM), a diagnostic tool to rapidly diagnose patients with complete and partial lipoprotein lipase deficiency (LPLD). AMT has developed Glybera(R) as a gene therapy for patients with this disease.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.
› Verified 3 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 71.9 | 79.6 |
| How often patients got better at getting in and out of bed | 71 | 81.1 |
| How often patients got better at bathing | 77.8 | 82.3 |
| How often patients’ breathing improved | 88.7 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 90.8 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 69.5 | 75 |
| How often home health patients had to be admitted to the hospital | 15.4 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 4 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 98.7 | 94 |
News Archive
The drop in criminal prosecutions indicates a shift for federal law enforcement agencies, which have increasingly targeted schemes aimed at mortgage lending, financial institutions and Medicare, the government [health] insurance plan for the elderly.
University of Sydney research provides new evidence that nanoparticles, which are present in many food items, may have a substantial and harmful influence on human health.
Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma announced today that the companies have entered into a development and commercialization agreement for LPLchip(TM), a diagnostic tool to rapidly diagnose patients with complete and partial lipoprotein lipase deficiency (LPLD). AMT has developed Glybera(R) as a gene therapy for patients with this disease.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.
› Verified 3 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
The drop in criminal prosecutions indicates a shift for federal law enforcement agencies, which have increasingly targeted schemes aimed at mortgage lending, financial institutions and Medicare, the government [health] insurance plan for the elderly.
University of Sydney research provides new evidence that nanoparticles, which are present in many food items, may have a substantial and harmful influence on human health.
Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma announced today that the companies have entered into a development and commercialization agreement for LPLchip(TM), a diagnostic tool to rapidly diagnose patients with complete and partial lipoprotein lipase deficiency (LPLD). AMT has developed Glybera(R) as a gene therapy for patients with this disease.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.
› Verified 3 days ago
The patient survey data of Acute Home Healthcare Inc is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 82 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 79 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 73 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 76 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 66 | 78 |
News Archive
The drop in criminal prosecutions indicates a shift for federal law enforcement agencies, which have increasingly targeted schemes aimed at mortgage lending, financial institutions and Medicare, the government [health] insurance plan for the elderly.
University of Sydney research provides new evidence that nanoparticles, which are present in many food items, may have a substantial and harmful influence on human health.
Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma announced today that the companies have entered into a development and commercialization agreement for LPLchip(TM), a diagnostic tool to rapidly diagnose patients with complete and partial lipoprotein lipase deficiency (LPLD). AMT has developed Glybera(R) as a gene therapy for patients with this disease.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.
› Verified 3 days ago
Pinnacle Home Care Location: 9145 Narcoossee Rd Ste A-210, Orlando, Florida 32827 Ratings: Phone: (407) 483-5890 | |
Family Home Care Group Llc Location: 5401 S Kirkman Rd Ste 510, Orlando, Florida 32819 Ratings: Phone: (407) 401-9146 | |
Elite Home Health Of Central Florida Llc Location: 5104 N Orange Blossom Trl Ste 208, Orlando, Florida 32810 Ratings: Phone: (321) 262-8235 | |
Adventhealth Home Care Central Florida Location: 600 Courtland St Ste 300, Orlando, Florida 32804 Ratings: Phone: (407) 691-8200 | |
Orlando Health Home Care Location: 102 W Pineloch Ave Ste 23, Orlando, Florida 32806 Ratings: Phone: (407) 852-2747 | |
Kindred At Home Location: 4776 New Broad St Ste 110, Orlando, Florida 32814 Ratings: Phone: (407) 894-5703 |